The Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) has reviewed the donation of starting material for cell-based advanced therapies, in particular issues relating to donor selection and testing, and informed consent and traceability.
the potential risks of infection or genetic abnormality being transmitted by the donor, and how those risks could be mitigated
the challenges of informed consent, in a field where innovation is so rapid
the implications of traceability, when information may arise years after donation which could have significance for a donor or their family
SaBTO has identified principles and drawn up recommendations to support the development of cell-based advanced therapies and maximise donor and patient safety.